Literature DB >> 11932273

Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women.

Adrian S Dobs1, Tam Nguyen, Cindy Pace, Carla P Roberts.   

Abstract

Menopause is associated with decreased lean body mass and increased fat due to aging and declining hormone secretion. Estrogens or estrogen-progestins have been used to alleviate vasomotor symptoms. However, estrogen-androgen (E/A) therapy is also used for vasomotor symptom relief and has been shown to increase lean body mass while decreasing fat mass. The objective of this 16-wk, double-blind, randomized, parallel group clinical trial was to compare esterified estrogen plus methyltestosterone (1.25 mg estrogen + 2.5 mg methyltestosterone/d; E/A group) vs. esterified estrogen alone (1.25 mg/d; E group) on body composition. Forty postmenopausal women (mean age, 57 yr) participated. Compared with estrogen treatment alone, women in the E/A group increased their total lean body mass and reduced their percentage fat for all body parts (P < 0.05). After E/A treatment, there were statistically significant increases in lean body mass by 1.232 kg [0.181 +/- 0.004, 0.81 +/- 0.057, and 0.24 +/- 0.009 kg in the upper body (P = 0.021), trunk (P = 0.001), and lower body (P = 0.047), respectively]. In the E group, the increase was 0.31 +/- 0.004, 0.021 +/- 0.03, and 0.056 +/- 0.05 kg in the upper body, trunk, and lower body, respectively. In the E/A group, body fat was reduced by 0.90 kg (P = 0.18 for the trunk only), and percentage body fat declined by 7.4% (P < or = 0.05 for all body parts). Lower body strength increased by 23.1 kg (51 lb) in the E/A group vs. only 11 kg (24.25 lb) in the E group (P = 0.002 between groups). A statistically significant increase in weight (2.7 +/- 5.1 vs. 0.1 +/- 4.6 lb; P < 0.05) was observed in the E/A group compared with the E group. When subjects were given self-reporting questionnaires, more improvement was noted in sexual functioning and quality of life in the E/A group when compared with patients receiving E alone. There were no noteworthy side effects. In conclusion, E/A replacement therapy can improve body composition, lower-body muscle strength, quality of life, and sexual functioning in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11932273     DOI: 10.1210/jcem.87.4.8362

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Higher serum free testosterone concentration in older women is associated with greater bone mineral density, lean body mass, and total fat mass: the cardiovascular health study.

Authors:  Chevon M Rariy; Sarah J Ratcliffe; Rachel Weinstein; Shalender Bhasin; Marc R Blackman; Jane A Cauley; John Robbins; Joseph M Zmuda; Tamara B Harris; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

Review 2.  Do anabolic-androgenic steroids have performance-enhancing effects in female athletes?

Authors:  Grace Huang; Shehzad Basaria
Journal:  Mol Cell Endocrinol       Date:  2017-07-12       Impact factor: 4.102

3.  A rehabilitation exercise program to remediate skeletal muscle atrophy in an estrogen-deficient organism may be ineffective.

Authors:  Marybeth Brown; J Andries Ferreira; Andrea M Foley; Kaitlyn M Hemmann
Journal:  Eur J Appl Physiol       Date:  2011-04-17       Impact factor: 3.078

4.  Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics.

Authors:  R S Boxer; A Kleppinger; J Brindisi; R Feinn; J A Burleson; A M Kenny
Journal:  Age Ageing       Date:  2010-05-18       Impact factor: 10.668

Review 5.  Osteosarcopenia: the Path Beyond Controversy.

Authors:  Jesse Zanker; Gustavo Duque
Journal:  Curr Osteoporos Rep       Date:  2020-04       Impact factor: 5.096

6.  Effects of testosterone administration on cognitive function in hysterectomized women with low testosterone levels: a dose-response randomized trial.

Authors:  G Huang; W Wharton; T G Travison; M H Ho; C Gleason; S Asthana; S Bhasin; S Basaria
Journal:  J Endocrinol Invest       Date:  2014-11-28       Impact factor: 4.256

7.  Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial.

Authors:  Grace Huang; Shehzad Basaria; Thomas G Travison; Matthew H Ho; Maithili Davda; Norman A Mazer; Renee Miciek; Philip E Knapp; Anqi Zhang; Lauren Collins; Monica Ursino; Erica Appleman; Connie Dzekov; Helene Stroh; Miranda Ouellette; Tyler Rundell; Merilyn Baby; Narender N Bhatia; Omid Khorram; Theodore Friedman; Thomas W Storer; Shalender Bhasin
Journal:  Menopause       Date:  2014-06       Impact factor: 2.953

8.  Longitudinal assessment of the menopausal transition, endogenous sex hormones, and perception of physical functioning: the Study of Women's Health Across the Nation.

Authors:  Samar R El Khoudary; Candace K McClure; Trang VoPham; Carrie A Karvonen-Gutierrez; Barbara Sternfeld; Jane A Cauley; Naila Khalil; Kim Sutton-Tyrrell
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-01-24       Impact factor: 6.053

9.  Power training and postmenopausal hormone therapy affect transcriptional control of specific co-regulated gene clusters in skeletal muscle.

Authors:  Eija Pöllänen; Vidal Fey; Timo Törmäkangas; Paula H A Ronkainen; Dennis R Taaffe; Timo Takala; Satu Koskinen; Sulin Cheng; Jukka Puolakka; Urho M Kujala; Harri Suominen; Sarianna Sipilä; Vuokko Kovanen
Journal:  Age (Dordr)       Date:  2010-04-13

10.  Quality of life in women with microprolactinoma treated with dopamine agonists.

Authors:  Erika Cesar de Oliveira Naliato; Alice Helena Dutra Violante; Dayse Caldas; Adilson Lamounier Filho; Christiane Rezende Loureiro; Rosita Fontes; Yolanda Schrank; Rodrigo Gomes de Souza; Mario Vaisman; Ermelinda Guerra; Arantzazu Sebastian; Annamaria Colao
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.